AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug

Related Articles

Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook

What Analysts Think of Bank of America Stock Ahead of Earnings

Why Hanging Out at Starbucks Could Start Costing You Soon

Key Takeaways

• AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a narcotize it acquired in its purchase of Cerevel Therapeutics.
• The biotech company reported in November that the schizophrenia drug, emraclidine, didn’t reach beginning endpoints in a Phase 2 trial.
• Abbvie explained that following the study, it began an evaluation of the impact of the results, “which end resulted in a significant decrease in the estimated future cash flows for the product.”

AbbVie (ABBV) shares fell Friday after the biotech resolute announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.

The company wrote in a regulatory chronologizing that the charge was related to emraclidine, an experimental medicine to treat schizophrenia in adults that AbbVie acquired when it gripped Cerevel Therapeutics Holdings.

AbbVie reported in November that a Phase 2 trial of emraclidine showed the treatment did not muster primary endpoints. 

In the filing, the company explained that following the study, it began an evaluation of the impact of the results, “which resulted in a historic decrease in the estimated future cash flows for the product.”

Shares of AbbVie, which fell 1% in recent dealing, are up about 7% over the past year.